BE
Beam Therapeutics
BEAM · NASDAQ
$26.83 +0.48% (+$0.13)
1M -1.65%
Market Cap $2.76B
P/E Ratio -
Div. Yield -
ROE 7.70%
Bulios Fair Price
$17.75
33.8% downside
Current Price
$26.83
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BEAM is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
37 /100
Fair P/B 2.59x
P/S 17.69x
PEG N/A
Growth
100 /100
Growing Book val. growth 19.07%
Rev. growth 31.88%
FCF growth N/A
Profitability
5 /100
Weak FCF margin 238.90%
Op. margin 242.27%
Gross margin 18.93%
Quality
1 /100
Poor Asset turnover 0.11x
ROA 6.16%
ROIC 28.62%
Debt
69 /100
Low Current ratio 14.57x
Int. coverage -7.76x
Debt/Equity 0.23x
Stability
1 /100
Unstable Profitable years 0
EPS volatility 137.13%
Beta 2.21x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BEAM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Evans
Employees
540
Headquarters
Cambridge
Upcoming events
03 NOV
Earnings
Upcoming earnings report